癫痫患儿红细胞免疫功能与红细胞补体受体1密度相关基因多态性的关系
|
摘要
目的:研究癫痫患儿红细胞免疫粘附功能与红细胞CR1密度相关基因多态性的关系,试图揭示癫痫患儿红细胞免疫功能低下的遗传学基础。
方法:收集2010年4月~2010年8月于吉林大学第一医院儿科门诊就诊的60例首诊癫痫患儿和60例同期体检健康儿童。采用聚合酶链式反应-限制性片段长度多态性分析(PCR-RFLP)方法测定红细胞CR1密度相关基因多态性,红细胞免疫粘附活性采用红细胞C3b受体花环率和红细胞免疫复合物花环率的方法测定。
结果:(1)癫痫组患儿RBC-C3bRR和RBC-ICR花环率(%)显著低于对照组(P<0.01)。癫痫组内全身性发作和部分性发作之间红细胞免疫花环率比较无差异。癫痫组不同性别间红细胞免疫功能比较无差异。(2)癫痫组HH、HL和LL基因型频率分别为71.7%、21.7%和6.6%,对照组HH、HL和LL基因型频率分别为75.0%、15.0%和10.0%。两组ECR1基因型频率和等位基因频率比较无明显差异。癫痫组部分性发作HL基因型高于全身性发作(P<0.05),但HH和LL基因型分布在不同癫痫发作类型间无差异。癫痫不同发作类型等位基因频率比较无差异。癫痫组不同性别之间相同ECR1基因型频率和等位基因频率比较差异无显著性。(3)分别比较组间和组内ECR1不同基因型红细胞免疫花环数:癫痫组HH基因型RBC-C3bRR%和RBC-ICR%花环率较对照组相同基因型降低(P<0.01),癫痫组HL/LL基因型RBC-C3bRR%花环率较对照组相同基因型降低(P<0.05),而RBC-ICR%无明显差异,癫痫组内HH和HL/LL基因型间RBC-C3bRR%花环率比较无差异,癫痫组内HH基因型RBC-ICR%花环率较HL/LL基因型降低(P<0.01),对照组内HH和HL/LL基因型间RBC-C3bRR%和RBC-ICR%比较无明显差异。
结论:1、癫痫患儿存在红细胞免疫功能低下,认为红细胞免疫参与癫痫的病理生理过程。2、ECR1-HH基因型可能是导致癫痫患儿红细胞免疫功能低下的危险因素之一。
Objective:To study the relationship between erythrocyte complement receptor 1(ECR1) genomic density polymorphism and erythrocyte immune function in epilepsy children, trying to reveal the possible genetic mechanisms underlying erythrocyte immunological disfunction in epileptic children.
Methods:Sixty children initially diagnosed as epilepsy and 60 normal controls for general health examination in pediatric outpatient in our hospital were enrolled from April 2010 to August 2010. Erythrocyte C3b receptor rosette rate and RBC immune complex rosette rate were conducted to test the immune function of red blood cell adhesion function. The CR1 genomic density polymorphism of erythrocyte from the two groups was detected by polymerase chain reaction (PCR) and restriction fragment length polymorphism (PCR-RFLP) using HindⅢrestriction enzyme.
Results:(1)The ratio of RBC-C3bRR% and RBC-ICR% were significant lower in epilepsy than in normal controls (P<0.01). However, there was no difference of red cell immune function between children with generalized seizures and those with partial seizures. Similarly, no significant influence on red cell immune function by gender was found. (2) The ECR1 genotype frequencies of HH, HL, and LL were 71.7%、21.7% and 6.6% in epilepsy group, and were 75.0%、15.0% and 10.0% in control group, respectively. There were no significant difference of ECR1 genotype frequency and allele frequency between epilepsy group and the controls. The frequency of HL genotype was higher in generalized seizures subgroup than that of partial seizures subgroup (P<0.05), although there was no difference of the HH and LL genotype frequency between them. The frequencies of H or L allele in ECR1 gene were similar in different types of seizure subgroup. There were no differences of the frequencies of genotype and H/L allele between different genders in epilepsy group. (3) Compared the number of red blood cell immune rosette within and among groups of different ECR1 genotypes: The ratio of RBC-C3bRR% and RBC-ICR% were significant decreased in epileptic children with HH genotype of ECR1 than controls with the same ECR1 genotype (P<0.01). The rate of RBC-C3bRR% was decreased in epileptic children carried HL/LL genotype of ECR1 than controls with the same genotype (P<0.05) and there was no difference of RBC-ICR% rate between them. There was no difference of RBC-C3bRR% rate between HH and HL/LL genotype within epilepsy group. The RBC-ICR% rate of epileptic children carried HH genotype was decreased than those carried HL/LL genotype in epilepsy group (P<0.01). There was no significant difference of the ratio of RBC-C3bRR% and RBC-ICR% children with HH genotype and those with HL/LL genotypes within control group.
Conclusion:1,Erythrocyte immune function is decreased in childhood epilepsy, indicating that some mechanisms related to red blood cell immunity may implicate in epileptic pathogenesis. 2,ECR1-HH genotype maybe one of the risk factors which facilitate erythrocyte immune disfunction under epileptic condition.
方法:收集2010年4月~2010年8月于吉林大学第一医院儿科门诊就诊的60例首诊癫痫患儿和60例同期体检健康儿童。采用聚合酶链式反应-限制性片段长度多态性分析(PCR-RFLP)方法测定红细胞CR1密度相关基因多态性,红细胞免疫粘附活性采用红细胞C3b受体花环率和红细胞免疫复合物花环率的方法测定。
结果:(1)癫痫组患儿RBC-C3bRR和RBC-ICR花环率(%)显著低于对照组(P<0.01)。癫痫组内全身性发作和部分性发作之间红细胞免疫花环率比较无差异。癫痫组不同性别间红细胞免疫功能比较无差异。(2)癫痫组HH、HL和LL基因型频率分别为71.7%、21.7%和6.6%,对照组HH、HL和LL基因型频率分别为75.0%、15.0%和10.0%。两组ECR1基因型频率和等位基因频率比较无明显差异。癫痫组部分性发作HL基因型高于全身性发作(P<0.05),但HH和LL基因型分布在不同癫痫发作类型间无差异。癫痫不同发作类型等位基因频率比较无差异。癫痫组不同性别之间相同ECR1基因型频率和等位基因频率比较差异无显著性。(3)分别比较组间和组内ECR1不同基因型红细胞免疫花环数:癫痫组HH基因型RBC-C3bRR%和RBC-ICR%花环率较对照组相同基因型降低(P<0.01),癫痫组HL/LL基因型RBC-C3bRR%花环率较对照组相同基因型降低(P<0.05),而RBC-ICR%无明显差异,癫痫组内HH和HL/LL基因型间RBC-C3bRR%花环率比较无差异,癫痫组内HH基因型RBC-ICR%花环率较HL/LL基因型降低(P<0.01),对照组内HH和HL/LL基因型间RBC-C3bRR%和RBC-ICR%比较无明显差异。
结论:1、癫痫患儿存在红细胞免疫功能低下,认为红细胞免疫参与癫痫的病理生理过程。2、ECR1-HH基因型可能是导致癫痫患儿红细胞免疫功能低下的危险因素之一。
Objective:To study the relationship between erythrocyte complement receptor 1(ECR1) genomic density polymorphism and erythrocyte immune function in epilepsy children, trying to reveal the possible genetic mechanisms underlying erythrocyte immunological disfunction in epileptic children.
Methods:Sixty children initially diagnosed as epilepsy and 60 normal controls for general health examination in pediatric outpatient in our hospital were enrolled from April 2010 to August 2010. Erythrocyte C3b receptor rosette rate and RBC immune complex rosette rate were conducted to test the immune function of red blood cell adhesion function. The CR1 genomic density polymorphism of erythrocyte from the two groups was detected by polymerase chain reaction (PCR) and restriction fragment length polymorphism (PCR-RFLP) using HindⅢrestriction enzyme.
Results:(1)The ratio of RBC-C3bRR% and RBC-ICR% were significant lower in epilepsy than in normal controls (P<0.01). However, there was no difference of red cell immune function between children with generalized seizures and those with partial seizures. Similarly, no significant influence on red cell immune function by gender was found. (2) The ECR1 genotype frequencies of HH, HL, and LL were 71.7%、21.7% and 6.6% in epilepsy group, and were 75.0%、15.0% and 10.0% in control group, respectively. There were no significant difference of ECR1 genotype frequency and allele frequency between epilepsy group and the controls. The frequency of HL genotype was higher in generalized seizures subgroup than that of partial seizures subgroup (P<0.05), although there was no difference of the HH and LL genotype frequency between them. The frequencies of H or L allele in ECR1 gene were similar in different types of seizure subgroup. There were no differences of the frequencies of genotype and H/L allele between different genders in epilepsy group. (3) Compared the number of red blood cell immune rosette within and among groups of different ECR1 genotypes: The ratio of RBC-C3bRR% and RBC-ICR% were significant decreased in epileptic children with HH genotype of ECR1 than controls with the same ECR1 genotype (P<0.01). The rate of RBC-C3bRR% was decreased in epileptic children carried HL/LL genotype of ECR1 than controls with the same genotype (P<0.05) and there was no difference of RBC-ICR% rate between them. There was no difference of RBC-C3bRR% rate between HH and HL/LL genotype within epilepsy group. The RBC-ICR% rate of epileptic children carried HH genotype was decreased than those carried HL/LL genotype in epilepsy group (P<0.01). There was no significant difference of the ratio of RBC-C3bRR% and RBC-ICR% children with HH genotype and those with HL/LL genotypes within control group.
Conclusion:1,Erythrocyte immune function is decreased in childhood epilepsy, indicating that some mechanisms related to red blood cell immunity may implicate in epileptic pathogenesis. 2,ECR1-HH genotype maybe one of the risk factors which facilitate erythrocyte immune disfunction under epileptic condition.
引文
[1]朱长庚.神经-免疫-内分泌网络与癫痫发病机制的关系[J].解剖学报, 2002, 33(3):321-324.
[2]Orange JS, Hossny EM, Weiler CR, et al.2006.Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Journal of Allergy Clinical Immunology, 117(4S1):S525-S553.
[3]Feasby T ,Banwell B, Benstead T, et al.2007.Guidelines on the use of intravenous immune globulin for neurologic conditions.Transfus MedRev,21(2 S1):S57–S107.
[4]Verrot D, San-Marco M , Dravet C ,et al . Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy[J]. Am J Med, 1997,103 (1):33-37.
[5]Asadi-Pooya AA, Asadi-Pooya K. Antinuclear antibodies in children with epilepsy treated by carbamazepine[J].EpilepsyRes.2008;80(2-3): 229-230.
[6]郭文平,朱长庚,刘庆莹.白细胞介素1β对谷氨酸致痫大鼠海马mGluR2和GluR3mRNA表达的影响.解剖学报,2004,35:113-116.
[7]Dambinova SA.Monitoring of brain spiking activity and autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptors in blood serum of rats with cobalt-induced epilepsy.J Neurochem,1998,71(5):2088-2092.
[8]PeltolaJ.Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.Neurology, 2000, 55(1):46-50.
[9]Vianello M, Tavolato B, Giometto B.Glutamic acid decarboxylase autoantibodies and neurological disorders[J].Neurol Sci, 2002, 23(4): 145-151.
[10]Poletaev AB,Morozov SG, Gnedenko BB. Serum anti-S100b, anti-GFAP and anti- NGF autoantibodies of IgG class in healthy persons andpatients with mental and neurological disorders[J].Autoimmunity, 2000, 32:33-38
[11]Ranua J, Luoma K, Auvinen A,et al.Antimitochondrial antibodies in patients with epilepsy.Epilepsy&Behavior,2005,7:95-97.
[12]Bostantjopoulou S,Hatzizisi O,Argyropoulou O,et al. Immunological parameters in patients with epilepsy[J].FunctNeurol,1994,9(1):11-15.
[13]Basaran N,Hincal F,Kansu E,et al.Humoral and cellular immune parameters in untreated and phentoin or carbamazepine-treated epileptic patients[J]Int J Immuno pharmacol,1994,16(12):1071-1077.
[14]许继平,李玉莲,苗丰莲,等.免疫球蛋白治疗儿童难治性癫痫的近、远期疗效与体液免疫功能的研究[J].中国免疫学杂志,2003,19(9):648-650
[15]Ravizza T, Vezzani A: Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1receptor type 1 in the rat limbic system.Neuroscience, 2006,137, 301-308.
[16]Haspolat S, Baysal Y, Duman O, et al.: Interleukin-1alpha,interleukin-1 beta and interleukin-1Ra polymorphisms in febrile seizures. J Child-Neurol 2005,20(7),565-568.
[17]Vezzani A, Moneta D, Richichi C, et al.:Functional role of inflammatory cytokines and anti-Inflammaory molecules in seizures and epileptogenesis. Epilepsia, 2002,43S5,30-35.
[18]Sheng JG,Boop FA,Mrak RE, et al.Increased neurona l beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1alpha immunoreactivity.JNeurochem.1994, 63(5):1872-1879.
[19]Aarli JA: Epilepsy and the immune system. ArchNeurol, 2000, 57(12), 1689-1692.
[20]Bartfai T, Schultzberg M: Cytokines in neuronal cell types. NeurochemInt, 1993, 22, 435-444..
[21]Kubera M, Budziszewska B, Basta-Kaim A, et al.:Immunoeactivity inkainite model of epilepsy.Pol J Pharmacol,2001,53(5),541-545 .
[22]Szelenyi J: Cytokines and the central nervous system. BrainResBull, 2001, 54(4), 329-338.
[23]Peltola J, Palmio J, Korhonen L,et al.: Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures.EpilepsyRes,2000,41,205-211.
[24]Kanemoto K,Kawasaki J,Yuasa S,et al.Increased frequency of interleukin-1beta-511T allele in patients with temporal lobe epilepsy,hippocam- pal sclerosis, and prolonged febrile convulsion. Epilepsia, 2003, 44(6):796-799.
[25]VezzaniA: Brain inflammation and seizures. EpilepsyCurr, 2004, 4(2), 73-75.
[26]Vezzani A, Granata T: Brain inflammationin epilepsy:experimental and clinical evidence.Epilepsia,2005,46(11),1724-1743.
[27]向贇.癫痫大鼠海马IL-1β变化的研究[J].武汉大学学报(医学版), 2004,25(6):630-633.
[28]施晓容,候晓君,王柯.癫痫患儿血清IL-2、TNF-α水平变化与意义[J].海峡预防医学杂志,2007,13(4): 97-98.
[29]晓琴,雷水生,李正莉,等.细胞因子集免疫抑制剂对大鼠脑内神经递质的影响[J].精神医学杂志,2007,20(4): 198-201.
[30]Sinha S, Patil SA, Jayaleκshmy V,et al.Do cytoκines have any role in epilepsy? EpilepsyRes, 2008, 82(2-3):171-176.
[31]Penkowa M,Molinero A,Carrasco J,Hidalgo J.Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures.Neuroscience,2001,102 (4):805-818.
[32]Liimatainen S,Fallah M,Kharazmi E,et al.Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy.J Neurol,2009, 256(5):796-802.
[33]Godlevsky LS, Shandra AA, Oleinik AA, Vastyanov RS,Kostyushov VV,Timchishin OL:TNF-alpha in cerebral cortex and cerebellum is affected by amygdalar kindling but not by stimulation of cerebellum.Pol J Pharmacol,2002, 54(6), 655-660.
[34]Sayyah M,Beheshti S,Shokrgozar MA,Eslami-far A,Deljoo Z,Khabiri AR, HaeriRohani A:Antiepileptogenic and anticonvulsant activity of interleukin-1beta in amygdala-kindled rats.Exp Neurol,2005, 191(1), 145-153.
[35]Ravizza T, Rizzi M, Perego C, et al.Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia, 2005, 46(Supp15):113-117.
[36]Peltola J, Eriksson K, Keranen T: Cytokines and seizures.Arch Neurol. 2001, 58(7),1168-1169.
[37]Sinkovics JG., Horvath JC.Human natural killer cells: a comprehensive review.Int J Oncol, 2005, 27,5-47.
[38]Vezzani A.Inflammation and epilepsy.Epilepsy Curr, 2005, 5,1-6.
[39]Stêpie? K, Tomaszewski M, Czuczwar SJ: Profile of anticonvulsant activity and neuro protective effects of novel and potential antiepileptic drugs- anupdate. Pharm- acolRep, 2005,57,719-733.
[40]王晓青,韩静,刘瑾.卡马西平对癫痫患儿细胞免疫功能调节作用的研究[J].中国全科医学,2008,11(5): 389-390.
[41]Hulkkonen J, Koskikallio E, Rainesalo S,Keranen T,Hurme M,Peltola J:The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients.EpilepsyRes,2004, 59(2-3), 199-205.
[42]Nelson RA.The immune-adherence phenomenon: an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis[J].Science,1953,118(3077):733-737.
[43]Siegel I.The red-cell immune system [J].Lancet, 1981,2(8246):556-559.
[44]Pascual M, Schifferli JA.The binding of immune complexes by the erythrocyte complement receptor 1(CR1)[J]. Immunopharmacology, 1992, 24(2):101-106.
[45]Smith GP, Smith RA.Membrane-targeted complement inhibitors[J]. MolImmunol, 2001, 38(2-3):249-255.
[46]Cohn JH,Atkinson JP,Klickstein LB,et al.The C3b/C4b recepto r (CR1,CD35) on erythrocytes:methods for study of the polymorphisms[J]. MolImmunol, 1999, 36(13-14):819-825.
[47]Cornillet P, Philbert F, Kazatchkine MD,et al.Genomic determination of the CR1(CD35) density polymorphismon erythrocytes using polymerase chain reactionam plification and HindⅢrestriction enzyme digestion J.Immunol Methods, 1991,136(2): 193-197.
[48]Jones DRE.Detection of red cell sensitization by antibody and complement: current practice and further porspective.CompHaematolInt, 1993, 3:201-207.
[49]Gibson NC, Waxman FJ.Relationship between immune complex binding and release and the quantitative expression of the complement receptortype 1(CR1,CD35) on humanery throcytes[J].Clin.Immunol Immunopathol,1994,70(2):104-113.
[50]KumarA, Kumar A,Sinha S,et al. HindⅢgenomic polymorphism of the C3b receptor (CR1) in patient with SLE: Low erythrocyte CR1 expression is an acquired phenomenon[J]. Immunol Cell Biol, 1995, 73(5):457-462.
[51]王海滨,郭峰,惠晓阳.系统性红斑狼疮患者红细胞补体受体一型分子基因型与数量的测定及其意义[J]中华风湿病杂志,2000,4(3):140-142.
[52]林海青,石晓红,孙涛,等.系统性红斑狼疮患者红细胞补体受体Ⅰ型与淋巴细胞功能相关抗原-1表达的研究[J].山东医药,2003,43(1):17-18.
[53]Raju KR, Sivasankar B, Anand V,et al.Use of complement receptor1(CD35) assay in the diagnosis and prognosis of immune complex mediated glomerulopathies[J]. Asian Pac J Allergy Immunol, 2001, 19(1): 23-27.
[54]郭聂涛,杨进,李燕林,等.原发性肾病综合征患者红细胞CR1密度相关基因组多态性与临床疗效的相关性分析[J].实用中西医结合临床,2006,6(3):1-3.
[55]何庭宇,郭聂涛,杨进,等.原发性肾病综合征患者红细胞CR1密度相关基因及数量表达与黏附活性的测定及意义[J].中国卫生检验杂志,2005,12(15):1500-1501.
[56]蒋玉红,周冬,舒琏,等.再生障碍性贫血患者红细胞CR1基因组密度多态性分布的研究[J].中国免疫学杂志,2001,17(5):274.
[57]蒋玉红,刘华林,张忠国,等.缺铁性贫血患者红细胞补体受体Ⅰ型(CR1)基因组密度多态性分布的研究[J].中国小儿血液,2001,6(1):10-11.
[58]Cohen JH,Atkinson JP,Klickstein LB,et al.The C3b/C4b receptor (CR1,CD35) on erythrocytes:methods for study of the polymorphisms[J]. Mol Immunol, 1999, 36(13-14): 819-825.
[59]覃志坚,何印蕾,郑子敏,等.β-地贫血患者红细胞CR1基因组密度多态性的研究[J].中国现代医学杂志,2007,17(16):1938-1940.
[60]郭淑玉,周立音,王海涟,等.特发性血小板减少性紫癜患儿红细胞CR1基因型、红细胞免疫功能及其调节功能的探讨[J].中华血液学杂志,1998,19(3):143-145.
[61]姜丽萍,刘德斌,孙丽华,等.急性白血病病人ECR1基因多态性与红细胞免疫功能的关系[J].内蒙古医学院学报,2007,29(1):8-10.
[62]郭峰,赵书平,叶芳耘,等.肝癌患者红细胞CR1基因组密度多态性与红细胞免疫粘附肿瘤能力的相关性[J].世界华人消化杂志,1998,6(10):841- 843.
[63]王海滨,赵新平,郭峰.肝癌患者红细胞补体受体Ⅰ型分子及其基因多态性变化[J].中华医学检验杂志,2001,24(1):31-33.
[64]Currie MS,Vala M,Pisetsky DS,et al.Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders[J].Blood,1990,75(8):1699-1704.
[65]杨新潮,邬伟秀,郭峰,等.血液肿瘤患者红细胞CR1密度基因组多态性分[J].临床血液学杂志,1998,11(6):263-264.
[66]张乃红,冯玫,朱镭,等.造血与淋巴组织肿瘤患者红细胞补体受体1分子数量及其基因组密度多态性测定[J].白血病·淋巴瘤,2007,16(2):85-87.
[67]刘丽宏,单保恩,高玉环,等.非霍奇金淋巴瘤患者红细胞CR1基因多态性、表达数量级免疫功能的相关性[J].癌变畸变突变,2007,19(5):351-354.
[68]Miyaike J, Iwasaki Y, Takahashi A, et al.Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases[J]. Gut, 2002,51(4):591-596.
[69]董格峰,刘彩峰,肖迪,等.丙型肝炎和肝癌患者红细胞CR1分子基因的多态性及其数量表达[J].中华传染病杂志,2006,24(4):272-274.
[70]李阳,王海滨,黎雪茹.肝硬化患者红细胞补体受体1型分子密度相关基因多态性与其数量变化的研究[J].临床肝胆病杂志,2003,19(2):74-76.
[71]郭峰,赵书平,张乐之,等.乙型肝炎患者红细胞CR1密度相关基因多态性与CR1活性的相关性[J].上海免疫学杂志,1999,19(2):111-112.
[72]Ruuska PE, Ikaheimo I, Silvennoinen-Kassinen S,et al.Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon[J].Clin Exp Immunol, 1992, 89(1):18-21.
[73]卢大雷.Ⅱ型糖尿病患者红细胞天然免疫功能变化与CR1密度基因多态性的相关分析[J].中华微生物学和免疫学杂志,2003,23(5):332-334.
[74]Nagayasu E,Ito M,Akaki M,et al.CR1 density polymorphism onerythrocyrtes of falciparum malaria patients in Thailand[J]. Am J Trop Med Hyg, 2001,64(1-2):1-5.
[75]Rowe JA,Raza A,Diallo DA,et al.Erythrocyte CR1 expression level does not correlate with a HindⅢrestriction fragment length polymorphism in Africans;implications for studies on malaria susceptility[J].Genes Immun,2002, 3(8):497-500.
[76]李海林,金萍,黄永坤,等.反复呼吸道感染患儿红细胞CR1数量基因多态性及其红细胞免疫功能[J].免疫学杂志,2006,22(4):423-425.
[77]蒋玉红,王亚秋,孙宽周.支气管哮喘患儿红细胞CR1基因组密度多态性分布及对红细胞免疫功能影响[J].中国实验诊断学,2006,10(10):1206-1207.
[78]刘晓红,赵书平,王君松,等.银屑病患者红细胞CR1基因组密度多态性的研究[J].中国麻风皮肤病杂志,2004,20(1):24-25.
[79]武娜,肖君刚,白明杰.过敏性紫癜患者红细胞CR1分子数量及其活性的研究[J].中国皮肤病学杂志,2007,21(7):400-401.
[80]鞠海英,刘亚珍,刘永茂,等.碘化钾与酚/氯仿提取外周血基因组DNA方法的比较[J].中国生物制品学杂志,2006,19(5):532-533.
[81]姜红,张扬达,闻树群.癫痫患者红细胞免疫功能和循环免疫复合物的变化[J].中国神经免疫学和神经病学杂志,1995,2(2):90-93.
[82]Herrera AH,Xiang L,Martin SG,et al. Analysis of complement receptor type 1 (CR1) expression on erythrocytes and of CR1 allelic markers in Caucasian and African American populations[J].Clin Immunol Immunopathol,1998,87(2):176-183.
[2]Orange JS, Hossny EM, Weiler CR, et al.2006.Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Journal of Allergy Clinical Immunology, 117(4S1):S525-S553.
[3]Feasby T ,Banwell B, Benstead T, et al.2007.Guidelines on the use of intravenous immune globulin for neurologic conditions.Transfus MedRev,21(2 S1):S57–S107.
[4]Verrot D, San-Marco M , Dravet C ,et al . Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy[J]. Am J Med, 1997,103 (1):33-37.
[5]Asadi-Pooya AA, Asadi-Pooya K. Antinuclear antibodies in children with epilepsy treated by carbamazepine[J].EpilepsyRes.2008;80(2-3): 229-230.
[6]郭文平,朱长庚,刘庆莹.白细胞介素1β对谷氨酸致痫大鼠海马mGluR2和GluR3mRNA表达的影响.解剖学报,2004,35:113-116.
[7]Dambinova SA.Monitoring of brain spiking activity and autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptors in blood serum of rats with cobalt-induced epilepsy.J Neurochem,1998,71(5):2088-2092.
[8]PeltolaJ.Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.Neurology, 2000, 55(1):46-50.
[9]Vianello M, Tavolato B, Giometto B.Glutamic acid decarboxylase autoantibodies and neurological disorders[J].Neurol Sci, 2002, 23(4): 145-151.
[10]Poletaev AB,Morozov SG, Gnedenko BB. Serum anti-S100b, anti-GFAP and anti- NGF autoantibodies of IgG class in healthy persons andpatients with mental and neurological disorders[J].Autoimmunity, 2000, 32:33-38
[11]Ranua J, Luoma K, Auvinen A,et al.Antimitochondrial antibodies in patients with epilepsy.Epilepsy&Behavior,2005,7:95-97.
[12]Bostantjopoulou S,Hatzizisi O,Argyropoulou O,et al. Immunological parameters in patients with epilepsy[J].FunctNeurol,1994,9(1):11-15.
[13]Basaran N,Hincal F,Kansu E,et al.Humoral and cellular immune parameters in untreated and phentoin or carbamazepine-treated epileptic patients[J]Int J Immuno pharmacol,1994,16(12):1071-1077.
[14]许继平,李玉莲,苗丰莲,等.免疫球蛋白治疗儿童难治性癫痫的近、远期疗效与体液免疫功能的研究[J].中国免疫学杂志,2003,19(9):648-650
[15]Ravizza T, Vezzani A: Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1receptor type 1 in the rat limbic system.Neuroscience, 2006,137, 301-308.
[16]Haspolat S, Baysal Y, Duman O, et al.: Interleukin-1alpha,interleukin-1 beta and interleukin-1Ra polymorphisms in febrile seizures. J Child-Neurol 2005,20(7),565-568.
[17]Vezzani A, Moneta D, Richichi C, et al.:Functional role of inflammatory cytokines and anti-Inflammaory molecules in seizures and epileptogenesis. Epilepsia, 2002,43S5,30-35.
[18]Sheng JG,Boop FA,Mrak RE, et al.Increased neurona l beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1alpha immunoreactivity.JNeurochem.1994, 63(5):1872-1879.
[19]Aarli JA: Epilepsy and the immune system. ArchNeurol, 2000, 57(12), 1689-1692.
[20]Bartfai T, Schultzberg M: Cytokines in neuronal cell types. NeurochemInt, 1993, 22, 435-444..
[21]Kubera M, Budziszewska B, Basta-Kaim A, et al.:Immunoeactivity inkainite model of epilepsy.Pol J Pharmacol,2001,53(5),541-545 .
[22]Szelenyi J: Cytokines and the central nervous system. BrainResBull, 2001, 54(4), 329-338.
[23]Peltola J, Palmio J, Korhonen L,et al.: Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures.EpilepsyRes,2000,41,205-211.
[24]Kanemoto K,Kawasaki J,Yuasa S,et al.Increased frequency of interleukin-1beta-511T allele in patients with temporal lobe epilepsy,hippocam- pal sclerosis, and prolonged febrile convulsion. Epilepsia, 2003, 44(6):796-799.
[25]VezzaniA: Brain inflammation and seizures. EpilepsyCurr, 2004, 4(2), 73-75.
[26]Vezzani A, Granata T: Brain inflammationin epilepsy:experimental and clinical evidence.Epilepsia,2005,46(11),1724-1743.
[27]向贇.癫痫大鼠海马IL-1β变化的研究[J].武汉大学学报(医学版), 2004,25(6):630-633.
[28]施晓容,候晓君,王柯.癫痫患儿血清IL-2、TNF-α水平变化与意义[J].海峡预防医学杂志,2007,13(4): 97-98.
[29]晓琴,雷水生,李正莉,等.细胞因子集免疫抑制剂对大鼠脑内神经递质的影响[J].精神医学杂志,2007,20(4): 198-201.
[30]Sinha S, Patil SA, Jayaleκshmy V,et al.Do cytoκines have any role in epilepsy? EpilepsyRes, 2008, 82(2-3):171-176.
[31]Penkowa M,Molinero A,Carrasco J,Hidalgo J.Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures.Neuroscience,2001,102 (4):805-818.
[32]Liimatainen S,Fallah M,Kharazmi E,et al.Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy.J Neurol,2009, 256(5):796-802.
[33]Godlevsky LS, Shandra AA, Oleinik AA, Vastyanov RS,Kostyushov VV,Timchishin OL:TNF-alpha in cerebral cortex and cerebellum is affected by amygdalar kindling but not by stimulation of cerebellum.Pol J Pharmacol,2002, 54(6), 655-660.
[34]Sayyah M,Beheshti S,Shokrgozar MA,Eslami-far A,Deljoo Z,Khabiri AR, HaeriRohani A:Antiepileptogenic and anticonvulsant activity of interleukin-1beta in amygdala-kindled rats.Exp Neurol,2005, 191(1), 145-153.
[35]Ravizza T, Rizzi M, Perego C, et al.Inflammatory response and glia activation in developing rat hippocampus after status epilepticus. Epilepsia, 2005, 46(Supp15):113-117.
[36]Peltola J, Eriksson K, Keranen T: Cytokines and seizures.Arch Neurol. 2001, 58(7),1168-1169.
[37]Sinkovics JG., Horvath JC.Human natural killer cells: a comprehensive review.Int J Oncol, 2005, 27,5-47.
[38]Vezzani A.Inflammation and epilepsy.Epilepsy Curr, 2005, 5,1-6.
[39]Stêpie? K, Tomaszewski M, Czuczwar SJ: Profile of anticonvulsant activity and neuro protective effects of novel and potential antiepileptic drugs- anupdate. Pharm- acolRep, 2005,57,719-733.
[40]王晓青,韩静,刘瑾.卡马西平对癫痫患儿细胞免疫功能调节作用的研究[J].中国全科医学,2008,11(5): 389-390.
[41]Hulkkonen J, Koskikallio E, Rainesalo S,Keranen T,Hurme M,Peltola J:The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients.EpilepsyRes,2004, 59(2-3), 199-205.
[42]Nelson RA.The immune-adherence phenomenon: an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis[J].Science,1953,118(3077):733-737.
[43]Siegel I.The red-cell immune system [J].Lancet, 1981,2(8246):556-559.
[44]Pascual M, Schifferli JA.The binding of immune complexes by the erythrocyte complement receptor 1(CR1)[J]. Immunopharmacology, 1992, 24(2):101-106.
[45]Smith GP, Smith RA.Membrane-targeted complement inhibitors[J]. MolImmunol, 2001, 38(2-3):249-255.
[46]Cohn JH,Atkinson JP,Klickstein LB,et al.The C3b/C4b recepto r (CR1,CD35) on erythrocytes:methods for study of the polymorphisms[J]. MolImmunol, 1999, 36(13-14):819-825.
[47]Cornillet P, Philbert F, Kazatchkine MD,et al.Genomic determination of the CR1(CD35) density polymorphismon erythrocytes using polymerase chain reactionam plification and HindⅢrestriction enzyme digestion J.Immunol Methods, 1991,136(2): 193-197.
[48]Jones DRE.Detection of red cell sensitization by antibody and complement: current practice and further porspective.CompHaematolInt, 1993, 3:201-207.
[49]Gibson NC, Waxman FJ.Relationship between immune complex binding and release and the quantitative expression of the complement receptortype 1(CR1,CD35) on humanery throcytes[J].Clin.Immunol Immunopathol,1994,70(2):104-113.
[50]KumarA, Kumar A,Sinha S,et al. HindⅢgenomic polymorphism of the C3b receptor (CR1) in patient with SLE: Low erythrocyte CR1 expression is an acquired phenomenon[J]. Immunol Cell Biol, 1995, 73(5):457-462.
[51]王海滨,郭峰,惠晓阳.系统性红斑狼疮患者红细胞补体受体一型分子基因型与数量的测定及其意义[J]中华风湿病杂志,2000,4(3):140-142.
[52]林海青,石晓红,孙涛,等.系统性红斑狼疮患者红细胞补体受体Ⅰ型与淋巴细胞功能相关抗原-1表达的研究[J].山东医药,2003,43(1):17-18.
[53]Raju KR, Sivasankar B, Anand V,et al.Use of complement receptor1(CD35) assay in the diagnosis and prognosis of immune complex mediated glomerulopathies[J]. Asian Pac J Allergy Immunol, 2001, 19(1): 23-27.
[54]郭聂涛,杨进,李燕林,等.原发性肾病综合征患者红细胞CR1密度相关基因组多态性与临床疗效的相关性分析[J].实用中西医结合临床,2006,6(3):1-3.
[55]何庭宇,郭聂涛,杨进,等.原发性肾病综合征患者红细胞CR1密度相关基因及数量表达与黏附活性的测定及意义[J].中国卫生检验杂志,2005,12(15):1500-1501.
[56]蒋玉红,周冬,舒琏,等.再生障碍性贫血患者红细胞CR1基因组密度多态性分布的研究[J].中国免疫学杂志,2001,17(5):274.
[57]蒋玉红,刘华林,张忠国,等.缺铁性贫血患者红细胞补体受体Ⅰ型(CR1)基因组密度多态性分布的研究[J].中国小儿血液,2001,6(1):10-11.
[58]Cohen JH,Atkinson JP,Klickstein LB,et al.The C3b/C4b receptor (CR1,CD35) on erythrocytes:methods for study of the polymorphisms[J]. Mol Immunol, 1999, 36(13-14): 819-825.
[59]覃志坚,何印蕾,郑子敏,等.β-地贫血患者红细胞CR1基因组密度多态性的研究[J].中国现代医学杂志,2007,17(16):1938-1940.
[60]郭淑玉,周立音,王海涟,等.特发性血小板减少性紫癜患儿红细胞CR1基因型、红细胞免疫功能及其调节功能的探讨[J].中华血液学杂志,1998,19(3):143-145.
[61]姜丽萍,刘德斌,孙丽华,等.急性白血病病人ECR1基因多态性与红细胞免疫功能的关系[J].内蒙古医学院学报,2007,29(1):8-10.
[62]郭峰,赵书平,叶芳耘,等.肝癌患者红细胞CR1基因组密度多态性与红细胞免疫粘附肿瘤能力的相关性[J].世界华人消化杂志,1998,6(10):841- 843.
[63]王海滨,赵新平,郭峰.肝癌患者红细胞补体受体Ⅰ型分子及其基因多态性变化[J].中华医学检验杂志,2001,24(1):31-33.
[64]Currie MS,Vala M,Pisetsky DS,et al.Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders[J].Blood,1990,75(8):1699-1704.
[65]杨新潮,邬伟秀,郭峰,等.血液肿瘤患者红细胞CR1密度基因组多态性分[J].临床血液学杂志,1998,11(6):263-264.
[66]张乃红,冯玫,朱镭,等.造血与淋巴组织肿瘤患者红细胞补体受体1分子数量及其基因组密度多态性测定[J].白血病·淋巴瘤,2007,16(2):85-87.
[67]刘丽宏,单保恩,高玉环,等.非霍奇金淋巴瘤患者红细胞CR1基因多态性、表达数量级免疫功能的相关性[J].癌变畸变突变,2007,19(5):351-354.
[68]Miyaike J, Iwasaki Y, Takahashi A, et al.Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases[J]. Gut, 2002,51(4):591-596.
[69]董格峰,刘彩峰,肖迪,等.丙型肝炎和肝癌患者红细胞CR1分子基因的多态性及其数量表达[J].中华传染病杂志,2006,24(4):272-274.
[70]李阳,王海滨,黎雪茹.肝硬化患者红细胞补体受体1型分子密度相关基因多态性与其数量变化的研究[J].临床肝胆病杂志,2003,19(2):74-76.
[71]郭峰,赵书平,张乐之,等.乙型肝炎患者红细胞CR1密度相关基因多态性与CR1活性的相关性[J].上海免疫学杂志,1999,19(2):111-112.
[72]Ruuska PE, Ikaheimo I, Silvennoinen-Kassinen S,et al.Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon[J].Clin Exp Immunol, 1992, 89(1):18-21.
[73]卢大雷.Ⅱ型糖尿病患者红细胞天然免疫功能变化与CR1密度基因多态性的相关分析[J].中华微生物学和免疫学杂志,2003,23(5):332-334.
[74]Nagayasu E,Ito M,Akaki M,et al.CR1 density polymorphism onerythrocyrtes of falciparum malaria patients in Thailand[J]. Am J Trop Med Hyg, 2001,64(1-2):1-5.
[75]Rowe JA,Raza A,Diallo DA,et al.Erythrocyte CR1 expression level does not correlate with a HindⅢrestriction fragment length polymorphism in Africans;implications for studies on malaria susceptility[J].Genes Immun,2002, 3(8):497-500.
[76]李海林,金萍,黄永坤,等.反复呼吸道感染患儿红细胞CR1数量基因多态性及其红细胞免疫功能[J].免疫学杂志,2006,22(4):423-425.
[77]蒋玉红,王亚秋,孙宽周.支气管哮喘患儿红细胞CR1基因组密度多态性分布及对红细胞免疫功能影响[J].中国实验诊断学,2006,10(10):1206-1207.
[78]刘晓红,赵书平,王君松,等.银屑病患者红细胞CR1基因组密度多态性的研究[J].中国麻风皮肤病杂志,2004,20(1):24-25.
[79]武娜,肖君刚,白明杰.过敏性紫癜患者红细胞CR1分子数量及其活性的研究[J].中国皮肤病学杂志,2007,21(7):400-401.
[80]鞠海英,刘亚珍,刘永茂,等.碘化钾与酚/氯仿提取外周血基因组DNA方法的比较[J].中国生物制品学杂志,2006,19(5):532-533.
[81]姜红,张扬达,闻树群.癫痫患者红细胞免疫功能和循环免疫复合物的变化[J].中国神经免疫学和神经病学杂志,1995,2(2):90-93.
[82]Herrera AH,Xiang L,Martin SG,et al. Analysis of complement receptor type 1 (CR1) expression on erythrocytes and of CR1 allelic markers in Caucasian and African American populations[J].Clin Immunol Immunopathol,1998,87(2):176-183.